Loading...
Back to narrative

EMBLA: Share Buyback And Ukraine Mobility Initiative Will Support Steady Outlook

Analysts Lift Embla Medical hf Price Target on Stronger Growth and Improved Margins

EMBLA logo
EMBLA
AnalystConsensusTarget
Not Invested
Published 09 Feb 2025

Update shared on 05 Dec 2025

Previous
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-1.7%
7D
1.5%

Analysts have modestly raised their price target on Embla Medical hf., reflecting slightly lower perceived risk, a marginal uptick in long term profit margins, and a small increase in the expected future earnings multiple, while keeping their overall fair value estimate broadly unchanged at approximately $37.40 per share.

What's in the News

  • Opened a new prosthetic clinic in Kyiv as part of the three year "Iceland Supports Mobility in Ukraine" initiative, which targets high quality prosthetic care and rehabilitation for up to 1,000 Ukrainian amputees (Key Developments)
  • Announced that the Ukraine initiative, co financed with the Government of Iceland and implemented with charity partner Future for Ukraine (FFU), has a total estimated value of USD 11 million over three years (Key Developments)
  • Reiterated full year 2025 guidance for 5 to 6% organic sales growth, indicating confidence in near term demand and execution (Key Developments)
  • Completed a share buyback tranche totaling 1,449,010 shares, or about 0.34% of shares outstanding, for USD 7 million under the program announced on February 7, 2025 (Key Developments)

Valuation Changes

  • Fair Value Estimate remained unchanged at approximately $37.40 per share, indicating no material shift in the overall valuation outcome.
  • Discount Rate fell slightly from 7.42% to 7.36%, reflecting a modest reduction in perceived risk to Embla Medical hf.'s future cash flows.
  • Revenue Growth expectation edged down marginally from about 9.45% to 9.45%, a negligible adjustment that leaves the top line outlook effectively intact.
  • Net Profit Margin forecast increased slightly from roughly 10.63% to 10.65%, pointing to a small improvement in long term profitability assumptions.
  • Future P/E multiple rose modestly from about 24.6x to 24.8x, signaling a minor uplift in expected valuation relative to future earnings.

Have other thoughts on Embla Medical hf?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.